Adrenal function is related to prognosis in moderate community-acquired pneumonia

European Respiratory Journal

Volumn 36, Issue 3, 2010, Pages 615-621

  Kolditz, M ^a   Halank, M ^a   Schulte Hubbert, B ^a   Hoffken G ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Adrenal function; Community acquired pneumonia; Cortisol; Prognosis; Risk prediction

Indexed keywords

C REACTIVE PROTEIN; CORTICOTROPIN; HYDROCORTISONE; INTERLEUKIN 6; PRASTERONE; PRASTERONE SULFATE; PROCALCITONIN; TETRACOSACTIDE; TUMOR NECROSIS FACTOR ALPHA;

ADRENAL FUNCTION; ADRENAL INSUFFICIENCY; ADULT; AGED; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; CORTICOSTEROID BLOOD LEVEL; CRITICAL ILLNESS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; PNEUMONIA SEVERITY INDEX; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROVOCATION TEST; RECEIVER OPERATING CHARACTERISTIC; RESISTANCE BLOOD VESSEL; RISK ASSESSMENT;

ADRENAL GLANDS; ADULT; AGED; AGED, 80 AND OVER; COMMUNITY-ACQUIRED INFECTIONS; COMORBIDITY; HUMANS; HYDROCORTISONE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PNEUMONIA; PROGNOSIS; TREATMENT OUTCOME;

EID: 77956578386     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00191709     Document Type: Article

References (26)

1. Arlt W, Hammer F, Sanning P, et al. Dissociation of serum dehydroepiandrosterone and dehydroepiandrosterone sulfate in septic shock. J Clin Endocrinol Metab 2006; 91: 2548-2554.
2. Marx C, Petros S, Bornstein SR, et al. Adrenocortical hormones in survivors and nonsurvivors of severe sepsis: diverse time course of dehydroepiandrosterone, dehydroepiandrosterone sulfate, and cortisol. Crit Care Med 2003; 31: 1382-1388.
3. Marik PE, Pastores SM, Annane D, et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008; 36: 1937-1949.
4. Annane D, Maxime V, Ibrahim F, et al. Diagnosis of adrenal insufficiency in severe sepsis and septic shock. Am J Respir Crit Care Med 2006; 174: 1319-1326.
5. Lipiner-Friedman D, Sprung CL, Laterre PF, et al. Adrenal function in sepsis: the retrospective Corticus cohort study. Crit Care Med 2007; 35: 1012-1018.
6. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358: 111-124.
7. Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005; 171: 242-248.
8. Christ-Crain M, Stolz D, Jutla S, et al. Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia. Am J Respir Crit Care Med 2007; 176: 913-920.
9. Gotoh S, Nishimura N, Takahashi O, et al. Adrenal function in patients with community-acquired pneumonia. Eur Respir J 2008; 31: 1268-1273.
10. Labrie F, Belanger A, Cusan L, et al. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab 1997; 82: 2396-2402.
11. Hoffken G, Lorenz J, Kern W, et al. [S3-guideline on ambulant acquired pneumonia and deep airway infections.] Pneumologie 2005; 59: 612-664.
12. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998; 279: 1452-1457.
13. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-843.
14. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003; 348: 727-734.
15. Arafah BM. Hypothalamic pituitary adrenal function during critical illness: limitations of current assessment methods. J Clin Endocrinol Metab 2006; 91: 3725-3745.
16. Loria RM. β-androstenes and resistance to viral and bacterial infections. Neuroimmunomodulation 2009; 16: 88-95.
17. Oberbeck R. Therapeutic implications of immune-endocrine interactions in the critically ill patients. Curr Drug Targets Immune Endocr Metabol Disord 2004; 4: 129-139.
18. Salluh JI, Bozza FA, Soares M, et al. Adrenal response in severe community-acquired pneumonia: impact on outcomes and disease severity. Chest 2008; 134: 947-954.
19. Ramirez JA, Srinath L, Ahkee S, et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155: 1273-1276.
20. Menendez R, Torres A, Rodriguez de Castro F, et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004; 39: 1783-1790.
21. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: S27-S72.
22. Kruger S, Ewig S, Marre R, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008; 31: 349-355.
23. Huang DT, Angus DC, Kellum JA, et al. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest 2009; 136: 823-831.
24. Charles PE, Tinel C, Barbar S, et al. Procalcitonin kinetics within the first days of sepsis: relationship with the appropriateness of antibiotic therapy and the outcome. Crit Care 2009; 13: R38.
25. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006; 174: 84-93.
26. Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. New Engl J Med 2004; 350: 1629-1638.